NASDAQ:VRMLVermillion Stock Price, Forecast & News

Vermillion's stock was trading at $0.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRML shares have increased by 376.2% and is now trading at $4.00. View which stocks have been most impacted by Coronavirus.

Vermillion is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vermillion.

Vermillion, Inc. (NASDAQ:VRML) issued its earnings results on Thursday, August, 8th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $1.14 million for the quarter. Vermillion had a negative net margin of 307.31% and a negative return on equity of 155.25%. View Vermillion's earnings history.

News headlines about VRML stock have been trending very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vermillion earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Vermillion.

Vermillion saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 2,280,000 shares, an increase of 5.1% from the May 31st total of 2,170,000 shares. Based on an average daily trading volume, of 566,000 shares, the short-interest ratio is currently 4.0 days. Currently, 4.5% of the shares of the stock are sold short. View Vermillion's Current Options Chain.

Some companies that are related to Vermillion include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Heska (HSKA), Myriad Genetics (MYGN), Quotient (QTNT), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Akers Biosciences (AKER), GeneNews (GNWSF) and Achieve Life Sciences (ACHV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vermillion investors own include CombiMatrix (CBMX), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Idera Pharmaceuticals (IDRA), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), TrovaGene (TROV), Charter Communications (CHTR), Fluidigm (FLDM) and Magnachip Semiconductor (MX).

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRML stock can currently be purchased for approximately $4.00.

Vermillion has a market capitalization of $389.51 million and generates $4.54 million in revenue each year. Vermillion employs 43 workers across the globe.

The official website for Vermillion is www.vermillion.com.

Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]